/ PORTFOLIO

Boston, MA

Atalanta Therapeutics is a biotechnology company dedicated to finding solutions for intractable diseases of the central nervous system. Utilizing its novel platform of divalent small interfering RNA (di-siRNA), Atalanta is initially focused on advancing two lead programs through clinical proof-of-concept: KCNT1 (ATL-201) to treat a rare, life-threatening pediatric epilepsy and Pan HD (ATL-101) to address Huntington’s Disease.

logo-rivervest

© Copyright RiverVest® All Rights Reserved.